Home' Australian Pharmacist : December 2011 Contents Vol. 30 -- December #12, 2011
Continuing Professional Development
The articles in this series are independently researched and compiled by PSA commissioned authors and peer reviewed.
Note: The CPD questions are now at
the end of each article.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from the
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
Submit your answers before 1 February 2012
or fax/mail to:
(04) 381 4786
NZCP Mail address: NZCP CPD answers
PO Box 11 640
(03) 9389 4044
PSA Mail address: PSA CPD answers
PSA Victorian Branch
Level 1, 381 Royal Parade
PARKVILLE VIC 3052
online at www.psa.org.au and receive automatic feedback
Australian Pharmacist Continuing Professional Development (CPD) is a central
element of PSA's CPD&PI program. It is also part of the New Zealand College of
Pharmacists (NZCP) education program for NZ pharmacists.
The CPD section is recognised under the PSA CPD&PI program as a Group 2 activity.
Members can choose which articles they want to answer questions on and get CPD
credits based on the questions they answer. The credits allocated to each section
and the pass mark are shown with the questions.
CPD credits are allocated as follows: a minimum of 6 out of 8 questions correct
attracts 1.5 credits, a minimum of 4 out of 5 questions correct attracts 1 credit, and
a minimum of 3 out of 4 questions correct attracts three quarters of a credit.
If not submitting online, write the correct answers in the spaces provided on the
answer panel on the back of the address sheet, fill in your name, member number
and address details, then either mail or fax the answer page to the relevant address
and fax number for marking.
27. European Heart Rhythm Association; European
Association for Cardio-Thoracic Surgery. Camm AJ,
Kirchhof P, Lip GY, et al. Guidelines for the management
of atrial fibrillation: the Task Force for the Management
of Atrial Fibrillation of the European Society of
Cardiology (ESC). Eur Heart J. 2010 Oct; 31(19):
28. NSW Therapeutic Advisory Group. Indicators for Quality
Use of Medicines in Australian Hospitals. Percentage
of patients with atrial fibrillation that are discharged on
warfarin. Version 1. Aug 2007.
29. National Prescribing Service. Using antithrombotics
wisely in stroke prevention. NPS News. 2009; 62:1--4.
30. eTG complete. Cardiovascular [online]. Melbourne:
Therapeutic Guidelines; Jul 2011.
31. Rossi S, ed. Amiodarone. Australian Medicines
Handbook. Adelaide: AMH; 2011.
32. Zimetbaum P. Amiodarone for atrial fibrillation. NEJM.
2007 Mar 1; 356(9):935--41.
33. Joy TR, Hegele RA. Narrative Review: Statin-related
Myopathy. Ann Intern Med. 2009; 150:858--68.
34. Bereznicki L. Antithrombotics. Pharmaceutical Society
of Australia. ISBN: 978-0-9807235-0-2.
1. Which ONE of the following is
a) If amiodarone is ceased drug-
interactions may persist for
b) Most GPs do not receive discharge
summaries before seeing their
patient following hospitalisation.
c) Hypothyroidism is a risk factor for
d) Pharmacist-conducted inpatient
pharmaceutical counselling before
discharge can improve medication
e) CHADS2 score provides
guidance on risk of medication
2. The absolute risk of major and
minor bleeding is reduced
by approximately 30% in
warfarin-treated patients who
receive 2--3 home visits by an
accredited pharmacist within
10 days of hospitalisation.
3. Mr ML's annual risk of stroke is
4. In which ONE of the following
patient groups is it more
appropriate to avoid the use of
A score of 4 out of 5 attracts 1 CPD credit.
a) Patients who are at low to medium
risk of falls.
b) Patients who infrequently use
c) Patients with dementia.
d) Nursing home residents.
5. Which ONE of the following
statements is MOST
APPROPRIATE to Mr ML?
a) Dabigatran 150 mg twice daily
should be used for stroke
b) Because of the language barrier
warfarin therapy should not be
c) Because of significant risk of
bleeding and social circumstances,
warfarin should not be used.
d) A diagnosis of congestive heart
failure may decrease the clinical
need for warfarin.
Links Archive Australian Pharmacist January 2012 November 2011 Navigation Previous Page Next Page